FDA Approves Two New Drugs for Psoriatic Arthritis
Good news for the approximately two million Americans with psoriatic arthritis (PsA). Those with active disease now have two new treatment options: the U.S. Food and Drug Administration (FDA) in December approved both ixekizumab (Taltz) and tofacitinib (Xeljanz) for the treatment of PsA.
Continue reading FDA Approves Two New Drugs for Psoriatic Arthritis